Clinical Study to Assess the Equivalence of Tranexamic Acid vs Oxytocin in Reducing the PPH

Inclusion Criteria: * Subjects at the end of pregnancy ( 37-42 w ) at low risk of PPH Mean by low-risk of PPH subjects without any of the following risk factors : hypertension/preeclampsia, placental abruption during pregnancy , placenta previa , tocolysis two hours before delivery, multiple pregnancy , previous PPH, obesity ( BMI \> 35 ), anemia (Hb \< 7 g/dL), elective caesarean section , induction of labor, retention of placental material , polyhydramnios , fever during labor, use of high doses of heparin low molecular weight. * Subjects full capacity and the willingness to give written informed consent . Exclusion Criteria: * Subjects with preterm pregnancy (\<37 weeks ) or with prolonged pregnancy ( \> 42 weeks ) * Subjects at the end of pregnancy ( 37 weeks - 42 weeks ) with the following risk factors for PPH (Tab1.Protocol Study, vers.2.0 of 07/05/2016) * multiple pregnancy * History of thromboembolic disease or high incidence of thromboembolic events in family history ( patients at high risk of thrombophilia ) * Patients with Long - QT syndrome or who are taking drugs that cause QT prolongation * Intrauterine fetal Death * Epilepsy * Autoimmune disease Tab1 medical history : * Placental abruption during pregnancy * Placenta previa * Hypertension / preeclampsia * Previous PPH * Polyhydramnios * Obesity ( BMI \> 35 ) * Anemia ( \< 7 g / dL )